NASDAQ:RTRX - Retrophin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$21.56 +0.21 (+0.98 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$21.56
Today's Range$21.2701 - $21.74
52-Week Range$19.77 - $33.00
Volume184,171 shs
Average Volume343,294 shs
Market Capitalization$889.31 million
P/E Ratio-14.37
Dividend YieldN/A
Beta1.38
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$154.94 million
Book Value$7.46 per share

Profitability

Net Income$-59,730,000.00

Miscellaneous

Employees173
Market Cap$889.31 million
OptionableOptionable

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) released its quarterly earnings data on Thursday, July, 26th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.21. The biopharmaceutical company earned $41.33 million during the quarter, compared to the consensus estimate of $43.22 million. Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. Retrophin's quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 earnings per share. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Retrophin.

What price target have analysts set for RTRX?

4 Wall Street analysts have issued 12-month target prices for Retrophin's shares. Their forecasts range from $43.00 to $57.00. On average, they anticipate Retrophin's share price to reach $48.00 in the next year. This suggests a possible upside of 122.6% from the stock's current price. View Analyst Price Targets for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

Has Retrophin been receiving favorable news coverage?

News coverage about RTRX stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Retrophin earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Ms. Elizabeth E. Reed, Gen. Counsel & Corp. Sec. (Age 48)
  • Dr. William E. Rote, Sr. VP of R&D (Age 56)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director

Who are Retrophin's major shareholders?

Retrophin's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.10%), Macquarie Group Ltd. (5.49%), Bank of America Corp DE (2.97%), Dimensional Fund Advisors LP (2.80%), Broadfin Capital LLC (2.46%) and D. E. Shaw & Co. Inc. (1.88%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which institutional investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Jennison Associates LLC, Tavio Capital LLC, First Trust Advisors LP, Falcon Point Capital LLC, Prudential Financial Inc., PNC Financial Services Group Inc. and Oak Ridge Investments LLC. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.

Which institutional investors are buying Retrophin stock?

RTRX stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Macquarie Group Ltd., Two Sigma Investments LP, D. E. Shaw & Co. Inc., Handelsbanken Fonder AB, Perceptive Advisors LLC, Broadfin Capital LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $21.56.

How big of a company is Retrophin?

Retrophin has a market capitalization of $889.31 million and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.

What is Retrophin's official website?

The official website for Retrophin is http://www.retrophin.com.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  520
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel